



Supplementary Fig. 1. Consort diagram of the study. Of the 689 patients meeting the criteria, 295 were finally included for analysis in the basal-bolus insulin (BBI) group after excluding patients who were 17 years or younger, those whose medical records contained insufficient data, those presenting with hyperglycemic crisis, or those with other critical medical problems that may adversely affect glycemic management (period 2). For comparison, individuals treated between October 2004 and August 2007 (period 1) were retrospectively reviewed and recorded. Patients treated before October 2004 were excluded because of technical problems in collecting data from the clinical data warehouse; patients who were already on multiple daily injection therapy before admission in period 1 were also excluded. T2DM, type 2 diabetes mellitus; GDM, gestational diabetes mellitus; T1DM, type 1 diabetes mellitus; DKA, diabetic ketoacidosis; HHS, hyperosmolar hyperglycemic state; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin.